Advanced biologics technology platform for next-gen immunotherapies
Unlocking the power of T cells against oncogenic driver mutations.
Discovering and developing a novel class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers
Allogeneic CAR T (AlloCAR T ™) therapies for cancer (NASDAQ: ALLO)
Developing alteration-specific targeted therapies for the treatment of cancer
Integrated gene therapy company advancing medicines into the clinic
Developing targeted inhalation therapies for life-threatening pulmonary diseases
A novel asset-centric pharmaceutical company designed and built to advance a portfolio of highly validated programs
Developing life-transforming therapies for patients with serious muscle diseases. (NASDAQ: DYN)
Pioneering the next generation of oncolytic virus therapy to improve the treatment of patients with cancer
Pursuing therapies against some of the most intractable cancer targets (NASDAQ: KRON)
Developing cell therapies to treat autoimmune diseases
Personalized T cell therapies to treat cancer
Supporting biopharmaceutical clients through clinical development and commercialization
Dedicated to finding novel solutions for protein misfolding diseases
Pioneering complex-directed therapies to treat RAS-driven cancer types
Targeting the underlying genetic cause of disease for underserved patients.
Target Engaged: Broadening the reach and impact of precision medicine for oncology.
Transforming the discovery of novel G-protein-coupled receptors (GPCR)-targeted therapies
Harnessing the power of microglia for the treatment of neurodegenerative diseases
Developing novel therapies for the prevention and treatment of metastatic cancer